FDA Withdraws Approval for Wellcovorin (Leucovorin Calcium) Tablets

The U.S. Food and Drug Administration (FDA) has withdrawn approval for GlaxoSmithKline's new drug application (NDA) for Wellcovorin (leucovorin calcium) tablets, EQ 5 mg base and EQ 25 mg base. This action was taken because GSK informed the FDA that the drug is no longer marketed and requested the withdrawal of approval. The withdrawal is effective as of April 10, 2026. Existing inventory may continue to be dispensed until depleted or expired. This is a regulatory action affecting healthcare providers and patients who may have been prescribed this medication.

Context

Wellcovorin, or leucovorin calcium, was developed by GlaxoSmithKline and used in various medical treatments. The FDA approval process ensures that drugs meet safety and efficacy standards before reaching the market. The withdrawal comes after GSK's notification that the drug is no longer marketed, indicating a significant shift in its availability.

Why it matters

The FDA's withdrawal of approval for Wellcovorin signifies the end of a specific treatment option for patients. This decision impacts healthcare providers who prescribe this medication and patients who rely on it for their treatment. The action reflects the regulatory body's oversight in ensuring that marketed drugs are available and effective.

Implications

Patients who relied on Wellcovorin may face challenges in managing their conditions due to the lack of this medication. Healthcare providers will need to identify and recommend alternative therapies, which may not be as effective for all patients. This withdrawal could lead to increased scrutiny on the availability of similar medications in the future.

What to watch

Healthcare providers will need to consider alternative treatments for patients who were prescribed Wellcovorin. The depletion of existing inventory may lead to a transitional period where patients may experience changes in their treatment plans. Monitoring of patient outcomes during this transition will be crucial.